Want to join the conversation?
$AGN, a global pharmaceutical company, announces the launch of a generic version of Janssen's INVEGA (paliperidone extended-release tablets) in the U.S. $AGN is the first to receive the FDA approval for generic version of INVEGA. INVEGA extended-release tablets are used for the treatment of schizophrenia in adults and adolescents.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.